Navigation Links
GlaxoSmithKline Opens $600million Vaccine Plant In Singapore

New state-of-the-art vaccine plant to hire 200 staff in Singapore, GSK and the Singapore Economic Development Board (EDB) set up endowment fund.

Singapore (PRWEB) June 16, 2009 -- Singapore's pharmaceutical industry has moved into higher gear, with the opening of a state-of-the-art vaccine plant. The new plant is GlaxoSmithKline's (GSK) first primary vaccine manufacturing facility and its biggest investment in Asia. The plant, which involves a total investment of S$600 million, underscores GSK's strong commitment to Singapore.

GSK will initially employ about 200 staff and the company is investing in training and development to equip them with the skills and knowledge to operate the new facility.

In addition, as part of an ongoing effort to develop talent and leadership in Singapore, GSK is setting up a $30 million endowment fund here to nurture minds in the fields of green manufacturing and public health policy. The Singapore Economic Development Board (EBD) will boost the fund by a further $20 million.

GSK has had a strong presence in Singapore for the last 50 years since 1959. Besides the local pharmaceutical and consumer healthcare operations, Singapore serves as the headquarters for GSK's Asia-Pacific operations and houses the Singapore Research Centre at Biopolis. In addition to this new vaccine plant, GSK has two global manufacturing and supply sites located in Singapore. With more than 1000 staff, GSK's total investment in the city-state now exceeds S$1.5 billion.

Asia is emerging as a global powerhouse in the biomedical sciences industry, with its fast-expanding market and massive talent base. As a leading bio-cluster in Asia, Singapore provides access to world-class scientific and clinical excellence, excellent connectivity to key regional markets as well as strategic partnership opportunities with research institutes, corporate labs and public hospitals.

Leveraging Singapore's strong scientific and economic fundamentals, global biomedical sciences companies invested more than $500 million here in the year 2008 alone. A growing base of more than 50 global pharmaceutical, biotechnology and medical technology companies are carrying out R&D in Singapore, alongside 30 public-sector research and medical institutes. Amongst them, more than 10 leading multi-national companies have established their regional headquarters in Singapore. They include AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Merck, Quintiles and Sanofi-Aventis. Their continued confidence is testament to Singapore's position as a leading global manufacturing site for innovative medicines.

To find out more about working and living in Singapore, log on to Contact Singapore's website at or search for jobs at

For more information about Singapore's biomedical sciences sector, log on to the Singapore Economic Development Board's website at and the Agency for Science, Technology and Research's website at

About Contact Singapore

Contact Singapore is an alliance of the Singapore Economic Development Board and Ministry of Manpower. It aims to attract global talent to work, invest and live in Singapore.

With offices in Asia Pacific, Europe and North America, Contact Singapore is the one-stop center for those who wish to pursue a rewarding career in Singapore, as well as business leaders and entrepreneurs who are keen to invest in or initiate new business activities here. Contact Singapore actively links Singapore-based employers with global talent and provides updates on career opportunities and industry developments in Singapore. We work with private sector partners to facilitate the interests of potential individual investors in Singapore.

For more information on working, investing and living in Singapore, please visit


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands
2. GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus
3. Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009
4. GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
5. GlaxoSmithKline Update: Influenza A (H1N1)
6. GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
7. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
8. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
9. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
10. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
11. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
Post Your Comments:
Related Image:
GlaxoSmithKline Opens $600million Vaccine Plant In Singapore
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage ... style concert posters. This is one of Joplin's most famous and beautiful concert posters. ... University of Michigan in Ann Arbor. The According to Hawley, "It is hard to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
Breaking Medicine Technology: